Monarch Capital Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the third quarter, Holdings Channel reports. The institutional investor owned 70,556 shares of the company’s stock after buying an additional 307 shares during the period. Johnson & Johnson comprises 3.2% of Monarch Capital Management Inc.’s portfolio, making the stock its 5th largest position. Monarch Capital Management Inc.’s holdings in Johnson & Johnson were worth $8,335,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Americafirst Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $101,000. Tuttle Tactical Management LLC bought a new stake in Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. increased its stake in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. increased its stake in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. bought a new stake in Johnson & Johnson during the second quarter worth approximately $127,000. Hedge funds and other institutional investors own 64.13% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.5178% during mid-day trading on Tuesday, hitting $112.5442. 4,507,242 shares of the stock were exchanged. The firm has a 50-day moving average price of $115.97 and a 200 day moving average price of $118.40. The company has a market capitalization of $306.18 billion, a PE ratio of 19.7550 and a beta of 0.75. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The business earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same period in the prior year, the business earned $1.49 EPS. Johnson & Johnson’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post $6.72 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.83%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date is Friday, November 18th. Johnson & Johnson’s dividend payout ratio is presently 56.64%.

ILLEGAL ACTIVITY NOTICE: This news story was first published by Financial Market News and is owned by of Financial Market News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this news story can be read at http://www.financial-market-news.com/johnson-johnson-jnj-position-increased-by-monarch-capital-management-inc/1208829/.

A number of analysts have commented on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target on the stock in a research report on Monday, August 22nd. RBC Capital Markets set a $133.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Wednesday, November 9th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, September 20th. Argus restated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, October 21st. Finally, BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research report on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $121.02.

In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the stock in a transaction that occurred on Friday, October 21st. The stock was acquired at an average cost of $114.11 per share, with a total value of $99,846.25. Following the purchase, the director now owns 26,520 shares in the company, valued at $3,026,197.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.